T Cell Engagers are typically administered via intravenous infusion. The dosing schedule and duration of treatment depend on several factors, including the type and stage of cancer, the specific T Cell Engager being used, and the patient's overall health. Continuous monitoring is essential to manage potential side effects and to assess the patient's response to therapy.